Completed PHASE3 INTERVENTIONAL NCT00003322

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma

Sponsor: Gynecologic Oncology Group

Conditions Ovarian Cancer Primary Peritoneal Cavity Cancer

Interventions cisplatin paclitaxel quality-of-life assessment

Updated 7 times since 2017 Last updated: May 24, 2013 Started: Mar 31, 1998 Primary completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ovarian Cancer and Primary Peritoneal Cavity Cancer, this trial is completed. The trial is conducted by Gynecologic Oncology Group and has accumulated 7 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Feb 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Albany, United States , Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Bethesda, United States , Billings, United States , Birmingham, United States , Brooklyn, United States , Calgary, Canada and 49 more locations